Adult Vaccine Market Analysis
The global adult vaccine market was valued at US$ 20.59 Billion in 2023 and is projected to reach US$ 35.87 Billion by 2032, growing at a CAGR of 6.36% from 2024 to 2032. The rising prevalence of infectious diseases such as pneumococcal illness, influenza, and COVID-19, alongside increasing government and nonprofit immunization initiatives, is likely to drive this growth.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=adult-vaccines-market-company-adult-vaccines-sales-country-adult-vaccines-worldwide-analysis-19-p.php
Adult Vaccine Market Overview
Adult vaccines are designed to prevent infectious diseases and reduce the risk of complications, serious illness, and pathogen transmission among adults aged 18 and older. These vaccines help maintain immunity from those received during childhood or provide new protection through booster doses. Common vaccines for adults include those for influenza, pneumonia, shingles, human papillomavirus (HPV), hepatitis A and B, measles, mumps, rubella (MMR), and meningococcal disease. Regular immunizations such as the flu vaccine, recommended annually, and Tdap (tetanus, diphtheria, pertussis), given as a booster every ten years, are vital in maintaining public health.
Key Features of the Report
| Feature | Details |
| Base Year | 2023 |
| Forecast Period | 2024 – 2032 |
| Market Size in 2023 | US$ 20.59 Billion |
| Forecast Market Size in 2032 | US$ 35.87 Billion |
| CAGR (2024-2032) | 6.36% |
Key Diseases Targeted by Adult Vaccines
Several vaccines are recommended for adults to prevent a range of diseases:
- Pneumococcal Vaccination: Particularly advised for adults 65 years and older to prevent pneumonia, meningitis, and bloodstream infections.
- Shingles Vaccine: Recommended for adults over 50 to prevent shingles caused by the varicella-zoster virus.
- HPV Vaccination: For adults up to the age of 26, protecting against cervical and other cancers.
- Hepatitis A & B Vaccines: To prevent liver-related issues, especially in those at high risk.
Growth Factors Driving the Adult Vaccine Market
- Rising Prevalence of Adult Diseases: With longer life expectancy, aging populations are more susceptible to age-related diseases, such as pneumonia and shingles, fueling the demand for adult vaccines.
- Increasing Infectious Disease Transmission: As infectious diseases spread globally, vaccinations remain a key preventative measure.
- Government and Pharmaceutical Partnerships: Collaborations between governments and pharma companies to develop new vaccines and expand immunization programs are crucial to the market’s growth.
- New Product Approvals: The approval of innovative vaccines, such as GSK’s RSV vaccine for adults over 60, will drive market expansion.
Regional Market Overview
North America
North America leads the adult vaccine market, driven by a high rate of viral infections and significant governmental support for vaccine programs. In the U.S., the CDC recommends annual flu vaccines and regular doses of Tdap and pneumococcal vaccines, contributing to widespread adoption.
Key Players in the Adult Vaccine Market
- GlaxoSmithKline (GSK)
- AstraZeneca
- Sanofi Pasteur
- Pfizer, Inc.
- CSL Limited
Market News
- Merck’s V116 Trial (April 2024): Merck released Phase 3 results for its 21-valent pneumococcal conjugate vaccine, V116, showing promising safety and efficacy for adults 50+.
- WHO Recommendations for Pfizer-BioNTech Vaccine (August 2022): The WHO affirmed the safety and efficacy of the Pfizer-BioNTech COVID-19 vaccine for adult use.
Related Report:
Messenger RNA (mRNA) Vaccines & Therapeutics Market
Liver Disease Therapeutic Market
Disease-wise Market Breakdown
The market is segmented by disease types, including Influenza, HPV (Cervical Cancer), Shingles (Zoster), Pneumococcal, MMR, Hepatitis, and more.
About Us – Renub Research
Renub Research is a premier Market Research and Advisory company with over 15 years of experience in Business-to-Business Global Market Research, Business Surveys, and Management Consulting. We provide a wide range of specialized business research services designed to help organizations make informed decisions and achieve their highest potential.
We work closely with our clients to understand the challenges they face and offer actionable insights to address these challenges. Our services are aimed at identifying the necessary changes and strategic adjustments needed for companies to succeed in today’s competitive market. Our clients include leading organizations from a wide range of industries such as Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecommunications & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.
At Renub Research, we provide our clients with detailed and accurate market data to support decision-making based on both information and knowledge. Our firm is recognized for delivering comprehensive industry solutions that aid consultants, bankers, and executives in formulating effective business strategies and making sound management decisions.
Our team comprises skilled professionals with expertise across various fields, including finance, marketing, human resources, biotechnology, pharmaceuticals, IT, environmental science, and more. The insights derived from our studies form the foundation for crucial management decisions, such as strategies, organizational structure, technology adoption, and mergers and acquisitions.
We take pride in supporting top global players, providing not only IT solutions but also comprehensive market trend analysis and opportunities. Our research reports offer critical tools for managers in today’s competitive global economy, featuring information and insights, analysis and understanding, as well as forecasts and estimations to guide decision-making
